Unknown

Dataset Information

0

Therapeutic suppression of pulmonary neutrophilia and allergic airway hyperresponsiveness by a ROR?t inverse agonist.


ABSTRACT: Airway neutrophilia occurs in approximately 50% of patients with asthma and is associated with particularly severe disease. Unfortunately, this form of asthma is usually refractory to corticosteroid treatment, and there is an unmet need for new therapies. Pulmonary neutrophilic inflammation is associated with Th17 cells, whose differentiation is controlled by the nuclear receptor, ROR?t. Here, we tested whether VTP-938, a selective inverse agonist of this receptor, can reduce disease parameters in animal models of neutrophilic asthma. When administered prior to allergic sensitization through the airway, the ROR?t inverse agonist blunted allergen-specific Th17 cell development in lung-draining lymph nodes and attenuated allergen-induced production of IL-17. VTP-938 also reduced pulmonary production of IL-17 and airway neutrophilia when given during the allergen challenge of the model. Finally, in an environmentally relevant model of allergic responses to house dust extracts, VTP-938 suppressed production of IL-17 and neutrophilic inflammation, and also markedly diminished airway hyperresponsiveness. Together, these findings suggest that orally available inverse agonists of ROR?t might provide an effective therapy to treat glucocorticoid-resistant neutrophilic asthma.

SUBMITTER: Whitehead GS 

PROVIDER: S-EPMC6675583 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Therapeutic suppression of pulmonary neutrophilia and allergic airway hyperresponsiveness by a RORγt inverse agonist.

Whitehead Gregory S GS   Kang Hong Soon HS   Thomas Seddon Y SY   Medvedev Alexander A   Karcz Tadeusz P TP   Izumi Gentaro G   Nakano Keiko K   Makarov Sergei S SS   Nakano Hideki H   Jetten Anton M AM   Cook Donald N DN  

JCI insight 20190611


Airway neutrophilia occurs in approximately 50% of patients with asthma and is associated with particularly severe disease. Unfortunately, this form of asthma is usually refractory to corticosteroid treatment, and there is an unmet need for new therapies. Pulmonary neutrophilic inflammation is associated with Th17 cells, whose differentiation is controlled by the nuclear receptor, RORγt. Here, we tested whether VTP-938, a selective inverse agonist of this receptor, can reduce disease parameters  ...[more]

Similar Datasets

| S-EPMC2778149 | biostudies-literature
| S-EPMC5807863 | biostudies-literature
| S-EPMC11231371 | biostudies-literature
| S-EPMC2078678 | biostudies-literature
| S-EPMC6996596 | biostudies-literature
| S-EPMC7294715 | biostudies-literature
| S-EPMC7187189 | biostudies-literature
| S-EPMC8200568 | biostudies-literature
| S-EPMC4011123 | biostudies-other
| S-EPMC3284547 | biostudies-literature